Cite
HARVARD Citation
Powles, T. et al. (2020). Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet oncology. 21 (12), pp. 1563-1573. [Online].